Tiesheng Shi, Johan Berglund and Lars I. Elding
Reduction of
trans-[Pt(CN)4X2]2-
(X = Cl or Br) [as model compounds for antitumour-active
platinum(IV) pro-drugs] to
[Pt(CN)4]2- by L-methionine,
MeSR, has been studied at 25 °C in the range
0 < pH < 12 (X = Cl) and
0 < pH < 6 (X = Br) by
use of stopped-flow spectrophotometry. The stoichiometry is
[PtIV]:
[MeSR] ≈ 1
:
1; the reaction products are methionine S-oxide and
[Pt(CN)4]2- as identified by NMR and UV
spectroscopies, respectively. The kinetics is first order with respect
to the platinum(IV) and methionine concentrations and the
second-order rate constants have a small pH dependence. In analogy with
reduction of platinum(IV) complexes by thioglycolic acid,
cysteine, penicillamine and glutathione, a mechanism is postulated in
which [Pt(CN)4X2]2- is reduced by
the various protolytic species of methionine in parallel reactions. In
the transition state the thioether group of methionine is assumed to
interact with co-ordinated halide, mediating the electron transfer to
the platinum(IV) centre. The transition states for previously
studied reactions between
[Pt(CN)4X2]2- and thiols are
discussed in view of these results. It is concluded that
methionine-containing biomolecules may compete with thiol compounds for
reduction of platinum(IV) pro-drugs under acidic conditions,
and also in neutral solutions with low concentrations of
thiol-containing biomolecules.